Commonwealth Equity Services
ZNTL icon

Commonwealth Equity Services’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Commonwealth Equity Services’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298K Hold
61,412
– – ﹤0.01% 3763
2026
Q1 		$144K Hold
61,412
– – ﹤0.01% 4082
2025
Q4 		$82.9K Buy
61,412
+425
+0.7% +$619 ﹤0.01% 4133
2025
Q3 		$92K Hold
60,987
– – ﹤0.01% 4100
2025
Q2 		$71K Buy
60,987
+300
+0.5% +$396 ﹤0.01% 4120
2025
Q1 		$96K Sell
60,687
-3,258
-5% -$7.03K ﹤0.01% 4000
2024
Q4 		$194K Hold
63,945
– – ﹤0.01% 3773
2024
Q3 		$235K Buy
63,945
+3,250
+5% +$11.8K ﹤0.01% 3562
2024
Q2 		$248K Sell
60,695
-200
-0.3% -$2.23K ﹤0.01% 3476
2024
Q1 		$960K Buy
60,895
+6,640
+12% +$91.3K ﹤0.01% 2270
2023
Q4 		$822K Buy
54,255
+37,275
+220% +$544K ﹤0.01% 2310
2023
Q3 		$341K Buy
16,980
+6,730
+66% +$171K ﹤0.01% 2912
2023
Q2 		$289K Buy
+10,250
New +$246K ﹤0.01% 3082

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Commonwealth Equity Services's ZNTL Position: Q2 2026 in Review

Commonwealth Equity Services held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 61,412 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #3763.

Commonwealth Equity Services first reported a position in ZNTL in Q2 2023 and has held it in 13 quarters since. The position peaked at $960K in Q1 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Commonwealth Equity Services held 61,412 shares of Zentalis Pharmaceuticals worth $298K as of Q2 2026.
  • Commonwealth Equity Services left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #3763 holding.
  • Commonwealth Equity Services first reported a position in Zentalis Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Commonwealth Equity Services's Zentalis Pharmaceuticals position peaked at $960K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.